Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

4
Player Avatar SwingCorey (< 20) Submitted: 1/11/2010 10:59:05 AM : Underperform Start Price: $6.49 GERN Score: +129.99

Embryonic stem cell research, regardless of the current presidential/congressional support, is in trouble. They have not figured out how to fix the problems (e.g. cancerous tumors), yet "adult" stem cells (e.g., from dental pulp, bone marrow, and fatty deposits) are consistently meeting or exceeding expectations.

If voter sentiment continues as it has been, expect a Republican Congress in 2010 and maybe even a Republican president in 2012 - either one could rollback federal funding of embryonic stem cell research.

Combine funding cuts with research setbacks and Geron is in a LOT of trouble.

Report this Post 2 Replies
Member Avatar briansal (48.32) Submitted: 2/1/2010 11:52:07 PM
Recs: 1

This comment has very little credibility and is only in the money due to a recent stock market correction. This poster obviously knows very little about stem cell research and the likelihood of stem cell research being repealed in 2011 is nonsense. A very unscientific and politically non-astute post.

Member Avatar henryyves (< 20) Submitted: 2/3/2010 6:19:15 PM
Recs: 0

yes,and it's the oncology side of the house which will produce extraordinary revenues. Geron will defeat cancer...nuff...

Featured Broker Partners


Advertisement